Citigroup Inc. Cuts Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)
Citigroup Inc. reduced its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report) by 39.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,459 shares of the medical instruments supplier’s stock after selling 1,598 shares during the period. Citigroup Inc.’s holdings in Mesa Laboratories were worth $258,000 at the end of the […] Citigroup Inc. reduced its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 39.4% during the 3rd quarter. The fund owned 2,459 shares of the medical instruments supplier’s stock after selling 1,598 shares during the period. Citigroup's holdings were worth $258,000 at the end of the most recent reporting period. Other institutional investors have also recently modified their holdings in the business. BlackRock Inc. raised its holdings in Mesa Labs by 0.4%. Vanguard Group Inc. increased its stake in shares of Mesa Laboratories by 1.3%. Invesco Ltd. lifted their position in Shares of Mesa Labs 0.7% in the 1st quarter, and Ranger Investment Management L.P increased its holdings by 3.9%.
Published : 4 weeks ago by Defense World Staff in Finance
Citigroup Inc. reduced its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report) by 39.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,459 shares of the medical instruments supplier’s stock after selling 1,598 shares during the period. Citigroup Inc.’s holdings in Mesa Laboratories were worth $258,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of the business. BlackRock Inc. raised its holdings in Mesa Laboratories by 0.4% in the 1st quarter. BlackRock Inc. now owns 924,948 shares of the medical instruments supplier’s stock worth $235,751,000 after purchasing an additional 4,061 shares during the period. Vanguard Group Inc. raised its stake in shares of Mesa Laboratories by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 341,492 shares of the medical instruments supplier’s stock worth $87,040,000 after buying an additional 4,464 shares during the period. Invesco Ltd. lifted its position in shares of Mesa Laboratories by 0.7% during the 1st quarter. Invesco Ltd. now owns 277,550 shares of the medical instruments supplier’s stock valued at $70,742,000 after buying an additional 1,898 shares in the last quarter. Morgan Stanley grew its stake in Mesa Laboratories by 808.7% in the 4th quarter. Morgan Stanley now owns 263,735 shares of the medical instruments supplier’s stock valued at $43,835,000 after acquiring an additional 234,712 shares during the period. Finally, Ranger Investment Management L.P. increased its holdings in Mesa Laboratories by 3.9% in the 2nd quarter. Ranger Investment Management L.P. now owns 233,043 shares of the medical instruments supplier’s stock worth $29,946,000 after acquiring an additional 8,677 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors and hedge funds.
Separately, Evercore ISI raised shares of Mesa Laboratories from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $100.00 to $125.00 in a report on Thursday, January 4th.
MLAB stock opened at $107.25 on Thursday. Mesa Laboratories, Inc. has a 12-month low of $82.86 and a 12-month high of $187.75. The business’s 50-day moving average is $101.03 and its 200 day moving average is $100.81. The company has a current ratio of 2.68, a quick ratio of 1.86 and a debt-to-equity ratio of 0.58. The stock has a market cap of $578.08 million, a price-to-earnings ratio of 630.92 and a beta of 0.83.
Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last released its earnings results on Monday, February 5th. The medical instruments supplier reported $1.46 earnings per share for the quarter, missing the consensus estimate of $1.47 by ($0.01). The firm had revenue of $53.47 million during the quarter, compared to analysts’ expectations of $54.90 million. Mesa Laboratories had a net margin of 0.45% and a return on equity of 7.41%. On average, sell-side analysts anticipate that Mesa Laboratories, Inc. will post 6.15 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Thursday, February 29th were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Wednesday, February 28th. This represents a $0.64 annualized dividend and a yield of 0.60%. Mesa Laboratories’s dividend payout ratio (DPR) is presently 376.49%.
Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.
• Five stocks we like better than Mesa Laboratories
• How to Invest in Biotech Stocks
• Best Bear Market Funds: Top 3 Investment Options to Consider
• Earnings Per Share Calculator: How to Calculate EPS
• Canadian Penny Stocks: Can They Make You Rich?
• Mid-Cap Stocks to Outperform the Market This Cycle
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report).
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
Topics: Markets